Skip to content
Sign in
Venture capitalBacked 1 network startup

PL Capital (Protocol Labs)

Investment arm linked to Protocol Labs; the only recorded data point is the oversubscribed $7.5M seed of brain-interface company Neurosoft.

Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
3most often with Connecticut Innovations

How they invest

The database row is empty (no thesis, sectors or stages). The only evidence is participation in Neurosoft Bioelectronics' seed, which suggests appetite for frontier neurotechnology; anything beyond that is unknown.

Stage and ticket

Unknown. Observed: participation in a $7.5M seed round (May 2026).

Geography

Unknown; the observed deal is a Swiss (Geneva) company with a New York subsidiary.

What makes them say yes

  • Frontier science with strong IP (inferred from the Neurosoft deal)
  • Credible academic origin (EPFL-style spin-off)
  • Unknown beyond this single deal

Red flags

  • Unknown: thesis not documented
  • Likely incremental software without deep-tech defensibility (inference)

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Use Neurosoft's founders as the warm route; their co-investors (Skybound, Connecticut Innovations, IAG Capital, Innosuisse) are also reachable. Confirm the fund's actual mandate before pitching.

Portfolio

1 network startup · no other company

Single recorded deal (Neurosoft Bioelectronics seed), so no pattern can be established.

Gaps in the portfolio

  • Thesis unknown: gaps cannot be assessed

Network startups

  • Neurosoft BioelectronicsSWC 2026 Finalist

    EPFL spin-off making soft, stretchable cortical electrodes for minimally invasive brain interfaces, with first-in-human epilepsy data and a $7.5M seed.

    Switzerland · MedTech & devices

    • Seed (oversubscribed) · $7.5M · 1 May 2026Source

Network startups that fit

3 analysed

IIT spin-off selling SiNAPS CMOS neural probes with 1,024 active electrodes for high-density brain recording, an option on brain-computer interfaces.

IIT spin-off making high-density neural probes, adjacent to Neurosoft's neural-interface field. Fit rests only on the single neurotech data point.

30%confidence

Evidence from the records

  • “Neurotechnology / neural probes”
  • “paving the way for brain-computer interfaces”
Intro path
Neurosoft Bioelectronics founders (same field).
First step
Ask Neurosoft's team how PL Capital diligenced the round, then pitch Corticale.

Uncertainty-quantification infrastructure that tells critical-AI operators when their models are unreliable and which data would fix it.

Reliability infrastructure for critical AI, including medicine; a frontier-AI angle that may fit a tech-forward investor, but no evidence of PL Capital AI deals.

15%confidence

Evidence from the records

  • “Reliability infrastructure for critical AI (robotics, defense, medicine, industry)”
  • “Trireme SDK and Gauloi platform described on the website”
First step
Confirm PL Capital's AI mandate before any outreach.

Tufts spin-off with an IRB-approved ingestible capsule that samples small-intestine microbiome and contents non-invasively.

Ingestible gut-sampling capsule from Tufts: frontier biomedical hardware at pre-seed, a loose analogue of the Neurosoft deal.

15%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Hold until PL Capital's mandate is confirmed.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Connecticut Innovations, IAG Capital Partners, and Skybound Venture Capital

Sources

  1. 1tech.eu/2026/05/20/neurosoft-bioelectronics-raises-75m-for-scalable

Profile compiled from public sources. Unknown fields are left empty rather than estimated.